Samuel Sendagala
Research Subjects
Samuel Sendagala has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Kailembo
Division of Global HIV and TB, U.S. Centers for Diseases Control and Prevention, Dar es Salaam, Tanzania
1 shared publication - Andrew C. Voetsch
Division of Global HIV and TB, Global Health Center, Centers for Disease Control and Prevention, USA
1 shared publication Augustina Delaney
Affiliation US Centers for Disease Control and Prevention, Global Health Center, Division of Global HIV and TB, Atlanta, Georgia, United States of America
1 shared publicationBernadette Ng'ENo
Affiliation US Centers for Disease Control and Prevention, Global Health Center, Division of Global HIV and TB, Atlanta, Georgia, United States of America
1 shared publication- Eduardo Samo Gudo
Instituto Nacional de Saúde
1 shared publication - Emilio Dirlikov
Affiliation Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
1 shared publication
Latest Publications
- Open Access
- 25 February 2026
- Published by Elsevier in SSRN Electronic Journal
Two Pathways to Unsuppressed Viral Load among Adults on Antiretroviral Therapy in Seven Sub-Saharan African Countries, 2019–2023: Virologic Failure Versus Treatment Interruption
Background: Achieving viral load suppression (VLS) among people with HIV on antiretroviral therapy (ART) remains a critical priority in sub-Saharan Africa. We aimed to determine the prevalence of virologic failure (VF) versus interruption in treatment (IIT) among adults with unsuppressed viral load using viral load testing combined with antiretroviral drug (ARV) detection.Methods: We analyzed Population-based HIV Impact Assessment (PHIA) survey data from seven sub-Saharan African countries (Eswatini, Lesotho, Malawi, Mozambique, Tanzania, Uganda, Zimbabwe) conducted during 2019–2023. Among participants aged ≥15 years with HIV who self-reported current ART use and ART initiation ≥4 months before the survey interview (n=14,834), we classified VLS (viral load <1,000 copies/mL), VF (viral load ≥1,000 copies/mL with detectable ARVs), and IIT (viral load ≥1,000 copies/mL without detectable ARVs). We examined adherence patterns and used survey-weighted Poisson regression to identify factors associated with VF and IIT.Findings: Overall VLS was 92.4% (95% CI 91.6–93.0), ranging from 89.4% in Mozambique to 96.9% in Malawi. Among all participants, 4.7% (95% CI 4.2–5.2) had VF and 3.0% (95% CI 2.5–3.5) had IIT. Younger adults (15–29 years) had significantly higher prevalence of both VF and IIT, with the strongest association observed for IIT (adjusted prevalence ratio [aPR] 7.61, 95% CI 4.47–12.97; vs ≥45 years). Men had significantly higher VF than women (aPR 1.62, 95% CI 1.20–2.18). Compared with dolutegravir-based regimens, efavirenz-based regimens (aPR 3.64, 95% CI 2.16–6.13) and nevirapine/atazanavir/lopinavir-based regimens (aPR 3.64, 95% CI 1.90–6.96) were each associated with VF. Suboptimal adherence was associated with VF (aPR 2.06, 95% CI 1.48–2.86) and IIT (aPR 1.78, 95% CI 1.16–2.75).Interpretation: In these seven sub-Saharan African countries, both VF and IIT were observed among people aged ≥15 years with unsuppressed viral load despite ART, with VF more common than IIT. Improving VLS may require complementary strategies to optimize ART regimens and strengthen adherence support, alongside efforts to prevent or rapidly reverse treatment interruptions, particularly among men and younger adults.
- 25 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTwo Pathways to Unsuppressed Viral Load among Adults on Antiretroviral Therapy in Seven Sub-Saharan African Countries, 2019–2023: Virologic Failure Versus Treatment Interruption
Background: Achieving viral load suppression (VLS) among people with HIV on antiretroviral therapy (ART) remains a critical priority in sub-Saharan Africa. We aimed to determine the prevalence of virologic failure (VF) versus interruption in treatment (IIT) among adults with unsuppressed viral load using viral load testing combined with antiretroviral drug (ARV) detection.Methods: We analyzed Population-based HIV Impact Assessment (PHIA) survey data from seven sub-Saharan African countries (Eswatini, Lesotho, Malawi, Mozambique, Tanzania, Uganda, Zimbabwe) conducted during 2019–2023. Among participants aged ≥15 years with HIV who self-reported current ART use and ART initiation ≥4 months before the survey interview (n=14,834), we classified VLS (viral load <1,000 copies/mL), VF (viral load ≥1,000 copies/mL with detectable ARVs), and IIT (viral load ≥1,000 copies/mL without detectable ARVs). We examined adherence patterns and used survey-weighted Poisson regression to identify factors associated with VF and IIT.Findings: Overall VLS was 92.4% (95% CI 91.6–93.0), ranging from 89.4% in Mozambique to 96.9% in Malawi. Among all participants, 4.7% (95% CI 4.2–5.2) had VF and 3.0% (95% CI 2.5–3.5) had IIT. Younger adults (15–29 years) had significantly higher prevalence of both VF and IIT, with the strongest association observed for IIT (adjusted prevalence ratio [aPR] 7.61, 95% CI 4.47–12.97; vs ≥45 years). Men had significantly higher VF than women (aPR 1.62, 95% CI 1.20–2.18). Compared with dolutegravir-based regimens, efavirenz-based regimens (aPR 3.64, 95% CI 2.16–6.13) and nevirapine/atazanavir/lopinavir-based regimens (aPR 3.64, 95% CI 1.90–6.96) were each associated with VF. Suboptimal adherence was associated with VF (aPR 2.06, 95% CI 1.48–2.86) and IIT (aPR 1.78, 95% CI 1.16–2.75).Interpretation: In these seven sub-Saharan African countries, both VF and IIT were observed among people aged ≥15 years with unsuppressed viral load despite ART, with VF more common than IIT. Improving VLS may require complementary strategies to optimize ART regimens and strengthen adherence support, alongside efforts to prevent or rapidly reverse treatment interruptions, particularly among men and younger adults.
- Open Access
- 23 May 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (5) , e0324122
Mortality rates in a cohort of infants attending immunization clinics in Uganda (2017–2019)
Background: Uganda reported a significant reduction in the mortality rate of children under 5 years of age, from 146/1,000 live births in 2000–42/1,000 live births in 2021. With the rollout of Option B+, the vertical transmission rate of HIV decreased from 13.0% (2012) to 6.0% (2019). However, its impact on the mortality rate among children is not well documented. We determined the mortality rate and associated risk factors among infants exposed and not exposed to HIV attending immunization clinics in Uganda. Methods: We conducted an observational prospective cohort study of mother–infant pairs (MIPs) with infants exposed or unexposed to HIV. We enrolled infants aged 4–12 weeks. The inclusion criteria were biological mothers attending health facilities that provide routine immunization for children and/or postnatal care visits who were able to provide signed written informed consent; mothers or infants who were not severely ill; and those who consented to have their infants tested for HIV antibodies at baseline and follow-up visits every 3 months until the children were aged 18 months. Child-HIV infection and death were censored events. Children lost to follow-up or withdrawn from the study were censored from analyses at the last documented study visit. The outcome of interest was child mortality, and the independent variables were mother’s age; infant HIV exposure status; infant sex; family socioeconomic status; marital status; education level; malaria during pregnancy; birth attendee; mother’s ART initiation; mode of transport to health facilities; breastfeeding pattern; 4 or more ANC visits; and mother’s baseline viral load nonsuppression and place of delivery. We used Kaplan–Meier survival curves to estimate cumulative mortality probability and the Wilcoxon log-rank test to compare differences in cumulative survival functions. We used multivariate Weibull proportional hazards and Weibull accelerated failure time (AFT) regression models with 95% confidence intervals (CIs) to identify factors associated with child death. Results: Among the 16,718 MIPs identified, 11,519 (68.9%) mothers consented to study follow-up. At the 18-month follow-up, 0.7% (79/11,519) of the infants had died, 40.5% (32/79) of whom were exposed to HIV. The overall child mortality rate per 1,000 person-years was 5.0 (95% CI: 4.0--6.2) and was significantly greater among the infants exposed to HIV (14.2; 95% CI: 10.0--20.0) than among the infants not exposed to HIV (3.5; 95% CI: 2.6--4.6). In the adjusted model, the mortality risk factors were HIV exposure status (aHR5.6 95% CI: 3.5--9.4), maternal age < 25 years (aHR1.8; 95% CI: 1.1--2.9), living without a partner (aHR1.8; 95% CI: 1.1--2.9), and delivery at home (aHR2.2; 95% CI: 1.3--4.0). Conclusion: Single young mothers living with HIV delivering at home increased the risk of child mortality. Identifying mothers with risk factors early for support could reduce the risk of child mortality.
- 23 May 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (5) , e0324122
Open AccessMortality rates in a cohort of infants attending immunization clinics in Uganda (2017–2019)
Background: Uganda reported a significant reduction in the mortality rate of children under 5 years of age, from 146/1,000 live births in 2000–42/1,000 live births in 2021. With the rollout of Option B+, the vertical transmission rate of HIV decreased from 13.0% (2012) to 6.0% (2019). However, its impact on the mortality rate among children is not well documented. We determined the mortality rate and associated risk factors among infants exposed and not exposed to HIV attending immunization clinics in Uganda. Methods: We conducted an observational prospective cohort study of mother–infant pairs (MIPs) with infants exposed or unexposed to HIV. We enrolled infants aged 4–12 weeks. The inclusion criteria were biological mothers attending health facilities that provide routine immunization for children and/or postnatal care visits who were able to provide signed written informed consent; mothers or infants who were not severely ill; and those who consented to have their infants tested for HIV antibodies at baseline and follow-up visits every 3 months until the children were aged 18 months. Child-HIV infection and death were censored events. Children lost to follow-up or withdrawn from the study were censored from analyses at the last documented study visit. The outcome of interest was child mortality, and the independent variables were mother’s age; infant HIV exposure status; infant sex; family socioeconomic status; marital status; education level; malaria during pregnancy; birth attendee; mother’s ART initiation; mode of transport to health facilities; breastfeeding pattern; 4 or more ANC visits; and mother’s baseline viral load nonsuppression and place of delivery. We used Kaplan–Meier survival curves to estimate cumulative mortality probability and the Wilcoxon log-rank test to compare differences in cumulative survival functions. We used multivariate Weibull proportional hazards and Weibull accelerated failure time (AFT) regression models with 95% confidence intervals (CIs) to identify factors associated with child death. Results: Among the 16,718 MIPs identified, 11,519 (68.9%) mothers consented to study follow-up. At the 18-month follow-up, 0.7% (79/11,519) of the infants had died, 40.5% (32/79) of whom were exposed to HIV. The overall child mortality rate per 1,000 person-years was 5.0 (95% CI: 4.0--6.2) and was significantly greater among the infants exposed to HIV (14.2; 95% CI: 10.0--20.0) than among the infants not exposed to HIV (3.5; 95% CI: 2.6--4.6). In the adjusted model, the mortality risk factors were HIV exposure status (aHR5.6 95% CI: 3.5--9.4), maternal age < 25 years (aHR1.8; 95% CI: 1.1--2.9), living without a partner (aHR1.8; 95% CI: 1.1--2.9), and delivery at home (aHR2.2; 95% CI: 1.3--4.0). Conclusion: Single young mothers living with HIV delivering at home increased the risk of child mortality. Identifying mothers with risk factors early for support could reduce the risk of child mortality.